行情

APTX

APTX

Aptinyx
NASDAQ

实时行情|Nasdaq Last Sale

4.415
-0.185
-4.02%
交易中 13:48 01/24 EST
开盘
5.00
昨收
4.600
最高
5.14
最低
4.210
成交量
89.31万
成交额
--
52周最高
6.10
52周最低
2.610
市值
1.39亿
市盈率(TTM)
-2.5658
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

APTX 新闻

  • 午盘:制造业PMI不及预期 美股下跌道指跌近100点
  • 新浪美股.1小时前
  • 数据显示Apple TV+四季度美国订阅用户达3360万
  • 新浪美股.2小时前
  • 迪斯尼+大获成功 大摩上调迪士尼目标价至170美元
  • 新浪美股.2小时前
  • 尚乘蔡志坚:数字化将进一步推动可持续发展
  • 新浪财经.2小时前

更多

所属板块

制药
-1.45%
制药与医学研究
-1.60%

热门股票

名称
价格
涨跌幅

APTX 简况

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
展开

Webull提供Aptinyx Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。